First Thing, Daily Maverick's flagship newsletter

Join the 230 000 South Africans who read First Thing newsletter.

We'd like our readers to start paying for Daily Maverick

More specifically, we'd like those who can afford to pay to start paying. What it comes down to is whether or not you value Daily Maverick. Think of us in terms of your daily cappuccino from your favourite coffee shop. It costs around R35. That’s R1,050 per month on frothy milk. Don’t get us wrong, we’re almost exclusively fuelled by coffee. BUT maybe R200 of that R1,050 could go to the journalism that’s fighting for the country?

We don’t dictate how much we’d like our readers to contribute. After all, how much you value our work is subjective (and frankly, every amount helps). At R200, you get it back in Uber Eats and ride vouchers every month, but that’s just a suggestion. A little less than a week’s worth of cappuccinos.

We can't survive on hope and our own determination. Our country is going to be considerably worse off if we don’t have a strong, sustainable news media. If you’re rejigging your budgets, and it comes to choosing between frothy milk and Daily Maverick, we hope you might reconsider that cappuccino.

We need your help. And we’re not ashamed to ask for it.

Our mission is to Defend Truth. Join Maverick Insider.

Support Daily Maverick→
Payment options

Covid Vaccine Makers Take Aim at Bottlenecks to Speed P...

Newsdeck

Newsdeck

Covid Vaccine Makers Take Aim at Bottlenecks to Speed Production

Glass vials move along a conveyor at the Gerresheimer AG medical glassware factory in Buende, Germany, on Tuesday, Aug. 11, 2020. Gerresheimer has built up capacity and most of its factories are operating around the clock as the company holds talks with pharma companies, working on a coronavirus vaccine. Photographer: Alex Kraus/Bloomberg
By Bloomberg
15 Jul 2021 0

(Bloomberg) --A new initiative aims to overcome bottlenecks that have hampered the production and global rollout of Covid-19 shots, linking manufacturers with suppliers of vital materials.

By James Paton
Jul 15, 2021, 8:23 AM
Word Count: 515

The platform, led by the Coalition for Epidemic Preparedness Innovations, will serve as a marketplace that matches up buyers and sellers of filters, lipids, vials, bioreactor bags and other key supplies used to make vaccines. The goal is to accelerate production of tens of millions of doses that can flow to Covax, the global distribution program that has fallen short of its initial targets.

Manufacturers see tackling component shortages as a way to address the inequitable access to vaccines that has left lower-income countries behind in the race to immunize. They have focused on eliminating bottlenecks and trade barriers, arguing against proposals to waive patent protection for shots. With an estimated 11 billion doses needed to escape the pandemic, some producers are struggling to hit full capacity.

“What we’re actually seeing is manufacturers unable to deliver the vaccines that they were promising just because of one small thing like a filter,” Melanie Saville, CEPI’s director of vaccine research and development, said in an interview. “This is a very practical solution for the short term.”

The head of Serum Institute of India, which is licensed to make vaccines from AstraZeneca Plc and Novavax Inc., warned earlier this year that a U.S. law blocking the export of key items including bags and filters would probably cause serious bottlenecks. Novavax’s own production, meanwhile, has been held up by shortages.

“We always knew that scaling up manufacturing would be as big a challenge as actually finding and developing effective vaccines,” said Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers & Associations in Geneva. “This is the biggest vaccination program in the history of mankind.”

Unequal Access

Facing criticism, the U.S. earlier this year decided to help India by sending items needed for shots as part of an aid package. The Biden administration also started sharing vaccines abroad after the country took the initial hundreds of millions of doses made on its soil. Wealthy nations have obtained most of the limited supplies of vaccines produced so far.

Vaccine supply chains can involve more than 100 components. The new platform will focus on several areas, including lipids. Messenger RNA, the genetic material at the heart of the Pfizer Inc. and Moderna Inc. shots, needs a protective shell composed of four different types of the fatty material — collectively called a lipid nanoparticle — so that it can enter human cells.

The new marketplace will allow manufacturers and suppliers to confidentially lodge requests or offers to Oslo-based CEPI. The program gives suppliers a way to allocate unused materials and mobilize idle stock from vaccine programs that have failed or plan to scale down. It also could tap surplus supplies from manufacturers not involved with vaccines.

“It’s not the only thing that needs to happen,” CEPI’s Saville said. “Our objective is to get those doses of vaccines out in a timely manner, and that’s why we’re looking at multiple approaches.”

© 2021 Bloomberg L.P.

Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]

Gallery

Please peer review 3 community comments before your comment can be posted